Stem Cells

S2 Genomics Announces Groundbreaking Single Cell FFPE Sample Prep Isolation Product

Retrieved on: 
Tuesday, April 9, 2024
Chemicals, Plastics, Electronic Design Automation, Manufacturing, Technology, Stem Cells, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Other Manufacturing, Other Technology, Biotechnology, Science, Research, Health, Genomics, Tissue, RNA, The central science, Antibiotics

S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The new FFPE sample prep isolation system is designed to isolate nuclei from FFPE tissue slices, enabling single-nucleus RNA sequencing (snRNA-Seq) for FFPE samples.
  • Jonathan Schimmel, President and CEO of S2 Genomics, expressed his enthusiasm for the new product: “The FFPE sample prep isolation system is a testament to our commitment to continuing innovation and excellence in the field of single cell genomics.
  • For more information about the FFPE sample prep isolation system and other S2 Genomics products, please visit us at s2genomics.com or connect with us on LinkedIn or Twitter .

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Stem Cells, Clinical Trials, Research, Science, Biotechnology, Cancer, Conference, Canaccord Genuity

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.
  • Details of the event are as follows:
    The Adicet Bio team will be available for one-on-one meetings throughout the conference.
  • Please contact your sales representative at Canaccord Genuity to register for a meeting with the company.

AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine

Retrieved on: 
Monday, April 8, 2024
Stem Cells, Biotechnology, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, KU Leuven, Mutation, Database, Survival, Best, DCR, Patient, Data, Aes, Șaeș, Progression-free survival, AACR, Kaplan–Meier estimator, Clinical trial, Cancer, Injection, ESMO, Safety, Symantec Endpoint Protection, DSMB, Poster, PFS, Vaccine, PDC

PDC*lung01 is the company’s off-the shelf therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC).

Key Points: 
  • PDC*lung01 is the company’s off-the shelf therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC).
  • The phase I/II trial (PDC-LUNG-101) aimed to assess the safety, tolerability, immunogenicity and preliminary clinical activity of PDC*lung01 in NSCLC patients, alone or in combination with anti-PD-1 treatment.
  • PDC*Line is reporting preliminary efficacy results for 19 evaluable patients in the B2 cohort that reached the 9-month PFS mark.
  • The final analysis of the clinical trial including the 45 patients from the B2 cohort will be conducted in Q3, 2024.

ViroCell to present at 2024 Cell & Gene Meeting on the Med

Retrieved on: 
Monday, April 8, 2024
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, GMP, Lentivirus, Organic

Complimentary attendance at this event is available for credentialed investors and members of the media only.

Key Points: 
  • Complimentary attendance at this event is available for credentialed investors and members of the media only.
  • Investors should contact Laura Stringham at [email protected] and interested media should contact Stephen Majors at [email protected] .
  • ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”) focused exclusively on the design and GMP manufacture of viral vectors for clinical trials.
  • Focused initially on manufacturing lentivirus and gamma-retrovirus vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk.

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Health, Medical Devices, Stem Cells, Genetics, General Health, Pharmaceutical, Biotechnology, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Research, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Cellistic Announces Successful CRISPR intellectual property Asset Purchase

Retrieved on: 
Thursday, April 4, 2024
Research, Genetics, Clinical Trials, Stem Cells, Other Health, Health, Pharmaceutical, Other Science, Science, Gene editing, Learning, Gene, Acquisition, IPS, Pulse, Society, CRISPR, Cell, IPSC, NK, Echo

Cellistic now offers partners a proprietary Cas-12 gene editing technology, with full freedom to operate, enabling custom edits to cell therapy candidates with higher precision than conventional CRISPR technologies.

Key Points: 
  • Cellistic now offers partners a proprietary Cas-12 gene editing technology, with full freedom to operate, enabling custom edits to cell therapy candidates with higher precision than conventional CRISPR technologies.
  • Pulse and Echo provide the optimal solution to accelerate the development of more consistent and cost-effective off-the-shelf allogeneic cell therapies.
  • Cellistic specializes in process development and manufacture of immune cell therapies based on human induced pluripotent stem cell (iPSC) technology using their Pulse and Echo Platform.
  • Interested in learning more about Cellistic and our new STAR-CRISPR technology, please reach out to our BD team.

Veristat Joins the Alliance for Regenerative Medicine (ARM) to Help Address Critical Issues Impacting the Advanced Therapy Sector

Retrieved on: 
Wednesday, April 3, 2024
Stem Cells, Consulting, Pharmaceutical, Oncology, Professional Services, Biometrics, General Health, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Health, Research, MED, Member, Regenerative medicine, Patient, ARM, Pharmaceutical industry

The announcement falls the week before members of Veristat’s Executive team are attending ARM’s Cell & Gene Meeting on the Med (#MeetingOnTheMed) being held in Rome, Italy.

Key Points: 
  • The announcement falls the week before members of Veristat’s Executive team are attending ARM’s Cell & Gene Meeting on the Med (#MeetingOnTheMed) being held in Rome, Italy.
  • “Advanced therapies have proven themselves as holding numerous benefits for patients struggling with rare and ultra-rare diseases, areas that account for 35% of our work,” stated Patrick Flanagan, Chief Executive Officer of Veristat.
  • “Veristat is proud to have supported the development of the first gene therapy approved in Europe.
  • ARM’s mission centers on enabling the development of advanced therapies and the modernization of healthcare systems so that patients benefit from durable, potentially curative treatments.

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 4, 2024
Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Webcast, Patient, Conference, Cancer

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m.

Key Points: 
  • Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m.
  • ET.
  • A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section.
  • A replay of the webcast will be archived and available for 30 days following the event.

Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers

Retrieved on: 
Tuesday, April 2, 2024
Stem Cells, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Medical Devices, Research, Hospitals, Science, Clinical Trials, HCC, Clinical Pediatrics, UCSF, AFP, Regenerative medicine, Patient, Hepatoblastoma, HB, CIRM, Cancer, Doctor of Philosophy, ARTEMIS, MD, Therapy, Hepatocellular carcinoma, Liver, Pharmaceutical industry

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).
  • The ARYA-2 trial is evaluating Eureka’s investigational ARTEMIS® ET140203 T-cell therapy which targets the alpha-fetoprotein (AFP)-peptide/HLA-A2 complex.
  • This therapy is designed to treat pediatric subjects (1 to 21 years) with relapsed or refractory liver cancer, including hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), and hepatocellular carcinoma (HCC).
  • For more information on the ARYA-2 trial, Eureka’s T-cell therapy platform, and the potential of this treatment, please visit eurekaconnectme.com .

Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech

Retrieved on: 
Tuesday, April 2, 2024
Other Health, Research, General Health, Oncology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Partner (business rank), France Biotech, Patient, Cancer, LEEM, Imagination, Creativity, Merck Group, IQVIA, Multimedia, Pharma, Pharmaceutical industry

Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .

Key Points: 
  • Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .
  • The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.
  • (France Biotech Press Release)
    This award testifies to the relevance of Brenus Pharma's mission: to restore the ability of cancer patients to fight resistant tumor cells and avoid relapses like never before.
  • Finally, congratulations to all the winning startups, nominees, and others who thrive and provide daily efforts for the health of patients."